About James La Rossa

This author has not yet filled in any details.
So far James La Rossa has created 176 blog entries.

What’s in a Name? For Some Psychiatrists, a Lot

By |2018-04-19T09:16:18-07:00April 18th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

The organization dedicated for decades to "Psychosomatic Medicine" will be rebranded as Consultation-Liaison Psychiatry. The name change, aimed in part at shedding the ambiguity around the word “psychosomatic” and better capturing the mission of consultation-liaison psychiatry, will be reflected across the group’s platforms. The tagline on the group’s journal, Psychosomatics, [...]

Anxiety and Depression May be Prevalent in Children with Comorbid Autism and ADHD

By |2018-04-19T09:16:58-07:00April 16th, 2018|We Know Psychiatry|

Children with comorbid autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) are at an increased risk of anxiety and mood disorders, a cross-sectional analysis has shown. “Our study supports that anxiety and mood disorders, although highly prevalent in those with ASD alone, are even more prevalent in individuals who have [...]

Powerful Ketamine Nasal Spray Shows Promise in Quickly Treating Depressive Symptoms

By |2018-04-19T09:17:31-07:00April 16th, 2018|We Know Psychiatry|

A more powerful ketamine (esketamine) nasal spray, combined with standard-of-care treatment, shows promise in quickly tamping-down depressive symptoms, according to results of a phase 2 study published April 16 in the American Journal of Psychiatry. In a study of 68 patients randomly assigned to either esketamine or placebo with standard-of-care treatment, [...]

Call For Papers — 2018 — 90-Day Fast Track Review

By |2018-04-19T09:18:06-07:00April 10th, 2018|We Know Psychiatry|

For Immediate Release April 10, 2018 Los Angeles CA www.medworksmedia.com Psychopharmacology Bulletin DIGITAL ISSN: 2472-2448; PRINT ISSN: 0048-5764 From: Michael E. Thase, MD, Editor-in-Chief James La Rossa Jr., Editorial Director This is a unique call for scientific papers to be submitted for publication in Psychopharmacology Bulletin. Accepted manuscripts will be [...]

The Use of Gabapentin in Acute Alcohol Withdrawal

By |2021-11-11T17:01:33-08:00March 22nd, 2018|Brief Bulletins from the Field, We Know Psychiatry|

Gabapentin’s anxiolytic and sedative properties along with its overall safety profile suggest that it may be a viable adjuvant to lorazepam in the management of acute alcohol withdrawal. By Christopher Wilming, Mariah Alford, and Lynnette Klaus On average, the required benzodiazepine dosage was lower with concomitant use of gabapentin in [...]

First for Big Pharma: Novartis Strikes Deal with Canadian Company to Distribute Medical Marijuana Products

By |2021-11-11T17:02:06-08:00March 19th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

In what may be the first foray by Big Pharma into the sale of medical marijuana products, Novartis has struck a deal with a Canadian company that sells medical cannabis products not only in its home country but also in Europe. Nanaimo, British Columbia-based Tilray announced today that it has a binding [...]

Lurasidone (Latuda) Gains FDA Approval for Bipolar Depression in Kids

By |2021-11-11T17:02:48-08:00March 11th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

The US Food and Drug Administration (FDA) has approved a supplemental new drug application for lurasidone (Latuda) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) in children and adolescents aged 10 to 17 years. Lurasidone, a serotonin dopamine antagonist, is already approved in the [...]

Viewpoint: Treating Bipolar Disorder Like Cancer

By |2021-11-11T17:03:00-08:00March 5th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

In a fascinating note in today's Journal of the American Medical Association (JAMA), Robert M. Post of the George Washington University School of Medicine attributes stigma as one of the main factors contributing to inadequate recognition and treatment of recurrent mood disorders, including unipolar depression and bipolar disorder. "This Viewpoint describes an [...]

Top 5 Articles of February 2018

By |2021-11-11T17:03:19-08:00March 1st, 2018|Brief Bulletins from the Field, We Know Psychiatry|

Top 5 Articles of February 2018 Updated for 2018 Dosing and Monitoring: Child and Adolescent Psychotropic Criteria For Children And Adolescents Psychotropic Drugs: Side Effects And Teratogenic Risks Recommended Clinical Monitoring Of Children And Adolescents For Psychotropic Drugs Internet Resources READ MORE A Pilot Evaluating Clinical Pharmacy Services in an [...]

Go to Top